Strong growth in both test volumes and revenues reported in Q1 indicates that MDxHealth is back on track after the disappointments of 2017. Following a successful $44m fundraising, topline growth at current levels promises to exceed our previous estimates. The company remains attractive at current levels. We reiterate our OUTPERFORM recommendation and €9 / share target price.

25 Apr 2018
Back on track in Q1

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Back on track in Q1
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
25 Apr 2018 -
Author:
Chris Redhead -
Pages:
6 -
Strong growth in both test volumes and revenues reported in Q1 indicates that MDxHealth is back on track after the disappointments of 2017. Following a successful $44m fundraising, topline growth at current levels promises to exceed our previous estimates. The company remains attractive at current levels. We reiterate our OUTPERFORM recommendation and €9 / share target price.